President and CEO of Innova Therapeutics, where he is devoted to developing innovative therapies for diseases with high unmet needs. He has more than 27 years of research/pharmaceutical/biotech experience, covering the global development process from preclinical through Phase IV. Prior to Innova Therapeutics, served as President and Chief Executive Officer of Scioderm, which he co-founded in 2013. In September 2015, Dr. Ryan led a deal to sell Scioderm to Amicus Therapeutics, totaling approximately $957 million.
He holds a doctorate degree in toxicology from the University of North Carolina at Chapel Hill, and he is board certified in toxicology. In addition, he holds advanced degrees in genetics and pharmacokinetics.
